Pathways of lymphatic spread in gynecologic malignancies

Area of Science:

• Radiology
• Oncology
• Gynecology

Background:

• Regional adenopathy in pelvic gynecologic tumors is crucial for prognosis and treatment planning.
• Identifying metastatic lymph nodes post-treatment is essential for assessing response and recurrence.
• Gynecologic cancers spread to pelvic and retroperitoneal lymph nodes, mirroring urologic neoplasm patterns.

Purpose of the Study:

• To review the significance of radiologic evaluation of lymph node involvement in gynecologic malignancies.
• To discuss staging systems (FIGO, TNM) and imaging modalities for assessing lymph node metastasis.
• To highlight the limitations of morphologic criteria and the advantages of functional imaging techniques.

Main Methods:

• Review of established staging systems: International Federation of Gynecology and Obstetrics (FIGO) and tumor, node, metastasis (TNM).
• Discussion of conventional imaging techniques: multidetector computed tomography (CT) and magnetic resonance (MR) imaging, focusing on morphologic criteria like nodal size.
• Exploration of advanced functional imaging techniques: diffusion-weighted MR imaging, positron emission tomography combined with CT, lymphoscintigraphy, and sentinel lymph node mapping.

Main Results:

• Nodal size, a primary morphologic criterion in CT and MR imaging, has limited diagnostic specificity for lymph node metastasis.
• Functional imaging techniques leverage molecular and physiologic activity for more precise evaluation of lymph node involvement.
• These advanced methods are increasingly incorporated into diagnostic imaging protocols for staging gynecologic malignancies.

Conclusions:

• Precise radiologic assessment of lymphadenopathy is fundamental in managing gynecologic cancers.
• While traditional imaging relies on size, functional techniques offer superior accuracy in detecting metastatic lymph nodes.
• Integrating advanced imaging modalities improves the staging and management of patients with gynecologic malignancies.